Company profile: Stellate
1.1 - Company Overview
Company description
- Provider of networking, database, recording, review, and analysis systems for electrical activity from the brain, serving EEG laboratories, epilepsy monitoring units, sleep laboratories, and intensive care units; engaged in the development, design, and manufacture of products for brain activity recording and analysis.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Stellate
Annovis Bio
HQ: United States
Website
- Description: Provider of treatments for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders, including: Buntanetap, an oral small molecule inhibiting multiple neurotoxic proteins; ANVS405, an IV formulation for acute neurodegeneration like TBI and stroke; and ANVS301, a Phase 1 compound aiming to increase cognitive capabilities in later-stage Alzheimer’s and dementia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Annovis Bio company profile →
SiteOne Therapeutics
HQ: United States
Website
- Description: Provider of novel non-opioid therapeutics and diagnostics for acute and chronic pain, including STC-004, an investigational NaV1.8-selective treatment; ST-2427, a highly selective NaV1.7 inhibitor for moderate-to-severe pain administered intravenously; and an inhaled NaV1.7-targeting therapy for chronic cough to reduce nerve fiber sensitivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SiteOne Therapeutics company profile →
Cognition Therapeutics
HQ: United States
Website
- Description: Provider of neurodegenerative disease therapeutics, developing CT1812, an oral sigma-2 receptor-targeting therapy aimed at slowing progression of Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration. The company conducts clinical trials on CT1812's safety and efficacy and researches sigma-2 receptor modulators to restore neuronal responses and prevent/displace toxic protein buildup in neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cognition Therapeutics company profile →
GeNeuro
HQ: Switzerland
Website
- Description: Provider of therapeutic monoclonal antibody drugs targeting human endogenous retroviral proteins for nervous system and autoimmune diseases. Portfolio includes Temelimab for Multiple Sclerosis and long-COVID neurological/psychiatric symptoms, the GNC-501 personalized trial in post-COVID W-ENV-positive patients, and a preclinical HERV-K Env antibody for sporadic ALS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeNeuro company profile →
Vigil Neuroscience
HQ: United States
Website
- Description: Provider of therapeutics and programs for neurodegenerative diseases, including iluzanebart (a fully human monoclonal antibody targeting TREM2) for ALSP, an oral small molecule TREM2 agonist program for common diseases like Alzheimer's, the ILLUMINATE natural history study and IGNITE Phase 2 trial in ALSP, and the ALSPAware no-cost genetic testing and counseling program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vigil Neuroscience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Stellate
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Stellate
2.2 - Growth funds investing in similar companies to Stellate
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Stellate
4.2 - Public trading comparable groups for Stellate
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →